Company news
Rain Enhancement Technologies Holdco, Inc. news in 2022
Rain Enhancement Technologies Holdco, Inc.'s news releases, calls and decks from 2022, newest first.
Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
December 28, 2022
Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 9, 2022
Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
November 3, 2022
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
November 3, 2022
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
October 25, 2022
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
August 3, 2022
Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 31, 2022
Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress
March 2, 2022
Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments
February 7, 2022
Calls in 2022
- Rain Enhancement Technologies Holdco (NASDAQ:RAIN) Q3 2022 Earnings Call
Nov 10, 2022
Transcript - Rain Enhancement Technologies Holdco (NASDAQ:RAIN) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Rain Enhancement Technologies Holdco (NASDAQ:RAIN) Q1 2022 Earnings Call
May 4, 2022
Transcript - Rain Enhancement Technologies Holdco (NASDAQ:RAIN) Q4 2021 Earnings Call
Mar 3, 2022
Transcript
Decks in 2022
- Rain Therapeutics — Investor Presentation (November 2022)
Investor deck · 24 slides · Nov 4, 2022